Two new drugs will soon be available to target little-known forms of high cholesterol, which are driven by our genes and ...

Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Dr Eric Berg DC is a ketosis and intermittent fasting expert, and he has shared the many benefits of turmeric, as well as how ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

Dr Eric Berg DC, who is known as The Knowledge Doc, has shared the 'amazing benefits' of taking half a teaspoon of a ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eating plant-based foods that are rich in fiber and healthy fats through what’s long been known as the portfolio diet is one ...

The results show that long-term use of antihypertensive drugs, cholesterol-lowering drugs, diuretics and blood-thinning drugs ...

An experimental oral drug called muvalaplin shows promise in reducing the cholesterol linked to heart disease in a study.